MoonLake Immunotherapeuti Ownership
| MLTX Stock | USD 39.67 0.91 2.24% |
MoonLake |
MoonLake Stock Ownership Analysis
About 15.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.89. MoonLake Immunotherapeuti had not issued any dividends in recent years. MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. Moonlake Immunotherapeuti is traded on NASDAQ Exchange in the United States. To find out more about MoonLake Immunotherapeutics contact Jorge Silva at 41 415108022 or learn more at https://www.moonlaketx.com.Besides selling stocks to institutional investors, MoonLake Immunotherapeuti also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different MoonLake Immunotherapeuti's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align MoonLake Immunotherapeuti's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
MoonLake Immunotherapeuti Quarterly Liabilities And Stockholders Equity |
|
About 15.0% of MoonLake Immunotherapeutics are currently held by insiders. Unlike MoonLake Immunotherapeuti's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against MoonLake Immunotherapeuti's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of MoonLake Immunotherapeuti's insider trades
MoonLake Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MoonLake Immunotherapeuti is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MoonLake Immunotherapeutics backward and forwards among themselves. MoonLake Immunotherapeuti's institutional investor refers to the entity that pools money to purchase MoonLake Immunotherapeuti's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Marshall Wace Asset Management Ltd | 2024-12-31 | 1.2 M | Polar Capital Holdings Plc | 2024-12-31 | 1.1 M | Alliancebernstein L.p. | 2024-12-31 | 1 M | Fred Alger Management, Llc | 2024-12-31 | 673.8 K | Hood River Capital Management Llc | 2024-12-31 | 649.6 K | Nuveen Asset Management, Llc | 2024-12-31 | 595.6 K | Ing Investment Management Llc | 2024-12-31 | 448.9 K | Finepoint Capital Lp | 2024-12-31 | 447.9 K | Camber Capital Management Llc | 2024-12-31 | 441 K | Bvf Inc | 2024-12-31 | 19.8 M | Cormorant Asset Management, Llc | 2024-12-31 | 8.5 M |
MoonLake Immunotherapeuti Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MoonLake Immunotherapeuti insiders, such as employees or executives, is commonly permitted as long as it does not rely on MoonLake Immunotherapeuti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MoonLake Immunotherapeuti insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MoonLake Immunotherapeuti Outstanding Bonds
MoonLake Immunotherapeuti issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MoonLake Immunotherapeuti uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MoonLake bonds can be classified according to their maturity, which is the date when MoonLake Immunotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
MoonLake Immunotherapeuti Corporate Filings
F4 | 3rd of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 26th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 12th of February 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.